United Therapeutics Stock News

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on Investo

United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2022 Results Conference Call May 4, 2022 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson, CEO Michael Benkow

United Therapeutics (UTHR) delivered earnings and revenue surprises of 69.93% and 12.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2022 financial results before t

United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t

David Bennett, 57, lived for two months after receiving the experimental organ transplant.

The first person to receive a heart transplant from a pig has died on Tuesday after two months from the landmark surgery at the University of Maryland Medical Center, the hospital…

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will p

Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease | Comunicados | Edición USA | Agencia EFE

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q4 2021 Results - Earnings Call Transcript

United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.

The heavy selling pressure might have exhausted for United Therapeutics (UTHR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street

United Therapeutics Corp (NASDAQ: UTHR ) and its partner MannKind Corp (NASDAQ: MNKD ) have received an FDA information request letter for additional information regarding the pulmonary safety of Tyvaso DPI . United Therapeutics responded to the agency''s information request. However, the FDA has considered this response to be a significant amendment to the NDA, extending FDA''s review deadline to May 2022 … Full story available on Benzinga.com